Trial Type: Kidney and Bladder Cancer

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Status: Open
Contact: Galina Lagos, MD
BrUOG 428
Targeting Androgen Receptor in bladder cancer. A Pilot Study of Degarelix in Combination with Neoadjuvant Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer.
Status: Open
Contact: Sheldon Holder, MD, PhD
A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Contact: Dr. Benedito Carneiro
LS-P-SODA: Phase I study of antibody-drug-conjugate (DS-3939) targeting tumors expressing TA-MUC-1
Contact: Dr. Benedito Carneiro
LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors
Contact: Dr. Benedito Carneiro
LS-P-START: A phase I study with a novel IL-2 (DF6215) for solid tumors
Contact: Dr. Benedito Carneiro
This drug causes immune activation by blocking PTPN2/N1. The study drug is given alone and in combination with PD-1 inhibitors. Cohorts in kidney cancer, head and neck, and other solid tumors.
Contact: Dr. Benedito Carneiro
inhibitor of MTAP for patients with MTAP gene alterations in gastric esophageal, NSCLC and bladder cancer
Contact: Dr. Benedito Carneiro